• Эмма Врамовна Вартанян
  • Кристина Ашотовна Цатурова
  • Екатерина Александровна Девятова
  • Анна Сергеевна Михайлюкова
  • Виталий Александрович Левин
  • Дмитрий Сергеевич Громенко
  • Александр Мкртичевич Гзгзян
  • Екатерина Евгеньевна Воропаева
  • Валерий Мстиславович Здановский
  • Олег Владимирович Сафронов
  • Татьяна Алексеевна Назаренко
Objective. To assess the quality of oocytes, embryos, and outcomes of in vitro fertilization (IVF) cycles in patients with diminished ovarian reserve (OR) who received inositol before infertility treatment. Subjects and methods. An observational comparative multicenter study pre-IVF TIDOR included 270patients. Group 1 (n=158) took inositol 4000 mg + folic acid 400цg (Inofert, Italfarmaco S.p.A., Italy); Group 2 (n=112) did not receive inositol before infertility treatment using IVF. The inclusion criteria were age <38years; a history of ovarian surgery; AMH <1.0 pg/ml, transfer of 42 embryos (ET) in the ovarian stimulation (OS) cycle. Results. In Group 1 and Group 2, mature oocytes (n=5 (0-7) and 2 (0- 5); p = 0.049) and good- quality embryos (42.2 and 30.1%; p = 0.049) were retrieved; there was a high rate of ET-induced pregnancy (38.1and 30.0%; p = 0.041). Conclusion. It is expedient to use inositol (Inofert, Italfarmaco S.p.A., Italy) in women younger than 38years after ovarian surgery in order to enhance
Original languageRussian
Pages (from-to)134-143
Number of pages9
JournalАКУШЕРСТВО И ГИНЕКОЛОГИЯ
Issue number8
StatePublished - 2019
Externally publishedYes

    Research areas

  • in vitro fertilization, infertility, inositol, Myo-inositol, ovarian reserve diminution, pregnancy, беременность, бесплодие, инозит, миоинозитол, снижение овариального резерва, экстракорпоральное оплодотворение

ID: 76582529